Views provided by UsageCounts
{"references": ["Ametamey, S.M.; Kessler, L.J.; Honer, M.; Wyss, M.T.; Buck, A.; Hintermann, S.; Auberson, Y.P.; Gasparini, F.; Schubiger, P.A. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J. Nucl. Med. 2006, 47, 698\u2013705. PMID: 16595505", "Ashburner, J.; Friston, K.J. Rigid body registration. In: Human Brain Function, 2nd ed.; Frackowiak, R.S.J., Ashburner, J., Penny, W.D., Zeki, S., Friston, K.J., Frith, C., Dolan, R., Price, C.J., Eds.; Academic: Waltham, Massachusetts, USA, 2004a, pp., 635-654", "Ashburner, J.; Friston, K.J. Rigid body registration. In: Human Brain Function, 2nd ed.; Frackowiak, R.S.J., Ashburner, J., Penny, W.D., Zeki, S., Friston, K.J., Frith, C., Dolan, R., Price, C.J., Eds.; Academic: Waltham, Massachusetts, USA, 2004b, pp., 635-654", "Benedict RHB et al. (1998) The Hopkins Verbal Learning Test-Revised: normative data and analysis of inter-form and test-retest reliability. Clin. Neuropsychol. 12: 43-55.", "Brandt J et al. (1998) Hopkins Verbal Learning Test-Revised (TM) [HVLT-R(TM)]. Par, Inc., Lutz, Florida, USA", "Cambridge Cognition Ltd. Cambridge Neuropsychological Test Automated Battery (CANTAB). Cambridge Cognition Ltd., Cambridge, UK, 2020. Available online: www.cambridgecognition.com (accessed 26 September 2020)", "Casta\u00f1eda, T.R.; de Prado, B.M.; Prieto, D.; Mora, F. Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. J. Pineal Res. 2004, 36, 177-185. doi: 10.1046/j.1600-079x.2003.00114.x. PMID: 15009508", "Deb S et al. (2007) Dementia Screening Questionnaire for Individuals with Intellectual Disabilities. Br J Psychiatry 190: 440-444. DOI: 10.1192/bjp.bp.106.024984. PMID: 17470960", "DeLorenzo, C.; Gallezot, J.-D.; Gardus, J.; Yang, J.; Planeta, B.; Nabulsi, N.; Ogden, R.T.; Labaree, D.C.; Huang, Y.H.; Mann, J.J.; Gasparini, F.; Lin, X.; Javitch, J.A.; Parsey, R.V.; Carson, R.E.; Esterlis, I. In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB. J. Cereb. Blood Flow Metab. 2017, 37, 2716\u20132727. DOI: 10.1177/0271678X16673646doi: 10.1177/0271678X16673646. Epub 2016 Jan 1. PMID: 27742888 PMCID: PMC5536783", "Folstein MF et al. (1975) \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12: 189-198. DOI: 10.1016/0022-3956(75)09226-6. PMID: 1202204", "Fuller, P.M.; Gooley, J.J.; Saper, C.B. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. J. Biol. Rhythms 2006, 21, 482-493. doi: 10.1177/0748730406294627. PMID: 17107938", "Kim, J.; Horti, A.G.; Mathews, W.B.; Pogorelov, V.; Valentine, H.; Brasic, J,R.; Holt, D.P.; Ravert, H.T.; Dannals, R.F.; Zhou, L.; Jedynak, B.; Kamiya, A.; Pletnikov, M.K.; Wong, D.F. Quantitative multi-modal brain autoradiography of glutamatergic, dopaminergic, cannabinoid, and nicotinic receptors in mutant disrupted-in-schizophrenia-1 (DISC1) mice. Mol. Imaging Biol. 2015, 17, 355-363. doi: 10.1007/s11307-014-0786-4. PMID: 25296765", "Lord C et al. (2012) Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2). Western Psychological Services (WPS), Torrance, California, USA", "Meng, T.; Yuan, S.; Zheng, Z.; Liu, T.; Lin, L. Effects of endogenous melatonin on glutatmate and GABA rhythms in the striatum of unilateral 6-hydroxydopamine-lesioned rats. Neuroscience 2015, 286, 308-315. doi: 10.1016/j.neuroscience.2014.11.062. Epub 2014 Dec 8. PMID: 25499317", "Roid GH. Stanford-Binet Intelligence Scales, 5th Edition (SB-5). Western Psychological Services (WPS), Torrance, California, USA, 2003", "Shapiro AM et al. (1999) Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin. Neuropsychol. 13: 348-358. DOI: 10.1076/clin.13.3.348.1749. PMID: 10726605", "Sparrow SS et al. (2020) Vineland Adaptive Behavior Scales, 3rd Edition (Vineland-3). Pearson, San Antonio, Texas, USA", "Dahlhaus R. (2018) Of men and mice: modeling the fragile X syndrome. Front Mol Neurosci 11, 41. DOI: 10.3389/fnmol.2018.00041. PMID: 29599705", "Innis, R.B.; Cunninghamm V.J.; Delforge, J.; Fujita, M.; Gjedde, A.; Gunn, R.N.; Holden, J.; Houle, S.; Huang, S.C.; Ichise, M.; Iida, H.; Ito, H.; Kimura, Y.; Koeppe, R.A.; Knudsen, G.M.; Knuuti, J.; Lammertsma, A.A.; Laruelle, M.; Logan, J.; Maguire, R.P.; Mintun, M.A.; Morris, E.D.; Parsey, R.; Price, J.C.; Slifstein, M.; Sossi, V.; Suhara, T.; Votaw, J.R.; Wong, D.F.; Carson, R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27, 1533-1539. doi: 10.1038/sj.jcbfm.9600493. Epub 2007 May 9. PMID: 17519979.", "Lammertsma, A.A.; Hume, S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 1996, 4, 153\u2013158. doi: 10.1006/nimg.1996.0066. PMID: 9345505", "Kuwabara, H.; Chamroonrat, W.; Mathews, W.; Waterhouse, R.; Brasic, J.; Guevara, M.R.; Kumar, A.; Hamill, T.; Mozley, P.D.; Wong, D.F. Evaluation of 11C- ABP688 and 18F -FPEB for imaging mGluR5 receptors in the human brain. J. Nucl. Med. 2011, 52 (supplement 1), 390. [abstract]", "Wong, D.F.; Waterhouse, R.; Kuwabara, H.; Kim, J.; Bra\u0161i\u0107, J.R.; Chamroonrat, W.; Stabins, M.; Holt, D.P.; Dannals, R.F.; Hamill, T.G.; Mozley, P.D. 18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. J. Nucl. Med. 2013, 54, 388-396. doi: 10.2967/jnumed.112.107995. Epub 2013 Feb 12. PMID: 23404089", "Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology, London, UK. Statistical Parametric Mapping (SPM). 2020. Available online: http://www.fil.ion.ucl.ac.uk/spm/", "Wienhard K, et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J. Comput. Assist. Tomogr. 1994, 18, 110-118. PMID: 8282858", "Sullivan JM, et al. Kinetic analysis of the metabotropic glutamate subtype 5 tracer [18F]FPEB in bolus and bolus plus-constant-infusion studies in humans. J. Cereb. Blood Flow Metab. 2013, 33, 532-541. doi: 10.1038/jcbfm.2012.195. PMID: 23250105.", "Sullivan J, et al. Test-retest evaluation of [F-18] FPEB, a PET tracer for the mGluR5 receptors in humans. J. Cereb. Blood Flow Metab. 2012, 32 (supplement 1), S122-S123 [abstract]", "Logan J, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996, 16, 834-840. doi: 10.1097;00004647-199609000-00008. PMID: 8784228", "Logan J, et al.The use of alternative forms of graphical analysis to balance bias and precision in PET images. J. Cereb. Blood Flow Metab. 2011, 31, 535-546. doi:10.1038/jcbfm.2010.123. PMID: 20808318.", "Ichise M, et al. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J. Cereb. Blood Flow Metab. 2002, 22 1271-1281. doi: 10.1097/01.WCB.0000038000.34930.4E. PMID: 1236866", "Fatemi SH, et al. Metabotropic glutamate receptor 5 tracer [18F]-FPEB displays increased binding potential in postcentral gyrus and cerebellum of male individuals with autism: a pilot PET study. Cerebellum Ataxias 2018, 5, 3. doi: 10.1186/s40673-018-0082-1. PMID: 29449954"]}
Table S1. Concomitant medications of participants with fragile X syndrome from the Institute for Neurodegenerative Disorders. Table S2. Demographic and clinical characteristics of participants from the Institute for Neurodegenerative Disorders (IND). All participant are non-Hispanic. Table S3. Demographic and clinical data of participants from Johns Hopkins University (JHU). Table S4. Genetic and psychological assessments of participants from the Institute for Neurodegenerative Disorders. Table S5. Genetic and psychological assessments of participants with fragile X syndrome and family members from Johns Hopkins University. Table S6. Positron emission tomography (PET) data and analyses for participants from the Institute for Neurodegenerative Disorders. Table S7. Positron Emission Tomography (PET) data and analysis of participants from Johns Hopkins University. The authors thank Flora Tassone, Ph.D., Department of Biochemistry and Molecular Medicine, School of Medicine, UC Davis Health, Sacramento, California, for providing genetic and protein data about participants.
This research was made possible by a Radiology BRidge/Development Funding Initiative to STimulate and Advance Research (RAD BriteStar Bridge) Award from the Johns Hopkins University School of Medicine, Baltimore, Maryland, to JRB; the Intellectual & Developmental Disabilities Research Center (U54 HD079123), Kennedy Krieger Institute, Johns Hopkins Medical Institutions. Baltimore, Maryland, to JRB; and the Johns Hopkins Institute for Clinical and Translational Research (ICTR), Johns Hopkins University School of Medicine, Baltimore, Maryland, to JRB, which is funded in part by Grant Number UL1 TR003098 from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS or NIH.
Binding potential, clinical trials, FMR1 gene, Fragile X Mental Retardation Protein (FMRP), genetic mutation, magnetic resonance imaging (MRI), mosaicism, neuropsychological testing, positron emission tomography (PET), 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([18F]FPEB), Binding potential, clinical trials, FMR1 gene, Fragile X Mental Retardation Protein (FMRP), genetic mutation, magnetic resonance imaging (MRI), mosaicism, neuropsychological testing, positron emission tomography (PET), 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([18F]FPEB)
Binding potential, clinical trials, FMR1 gene, Fragile X Mental Retardation Protein (FMRP), genetic mutation, magnetic resonance imaging (MRI), mosaicism, neuropsychological testing, positron emission tomography (PET), 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([18F]FPEB), Binding potential, clinical trials, FMR1 gene, Fragile X Mental Retardation Protein (FMRP), genetic mutation, magnetic resonance imaging (MRI), mosaicism, neuropsychological testing, positron emission tomography (PET), 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([18F]FPEB)
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
| views | 5 |

Views provided by UsageCounts